Nektar Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Nektar Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. 

CEO
Howard W. Robin
CEOHoward W. Robin
Employees
63
Employees63
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
1990
Founded1990
Employees
63
Employees63

NKTR Key Statistics

Market cap
2.57B
Market cap2.57B
Price-Earnings ratio
-9.31
Price-Earnings ratio-9.31
Dividend yield
Dividend yield
Average volume
823.05K
Average volume823.05K
High today
$78.82
High today$78.82
Low today
$74.85
Low today$74.85
Open price
$78.82
Open price$78.82
Volume
686.84K
Volume686.84K
52 Week high
$109.00
52 Week high$109.00
52 Week low
$7.99
52 Week low$7.99

Stock Snapshot

The current Nektar Therapeutics(NKTR) stock price is $76.01, with a market capitalization of 2.57B. The stock trades at a price-to-earnings (P/E) ratio of -9.31.

On 2026-05-13, Nektar Therapeutics(NKTR) stock traded between a low of $74.85 and a high of $78.82. Shares are currently priced at $76.01, which is +1.5% above the low and -3.6% below the high.

The Nektar Therapeutics(NKTR)'s current trading volume is 686.84K, compared to an average daily volume of 823.05K.

During the past year, Nektar Therapeutics(NKTR) stock moved between $7.99 at its lowest and $109.00 at its peak.

During the past year, Nektar Therapeutics(NKTR) stock moved between $7.99 at its lowest and $109.00 at its peak.

NKTR News

TipRanks 5d
Nektar Therapeutics Establishes New Equity Distribution Agreement

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

The Motley Fool 6d
Nektar Q1 2026 Earnings Transcript

Image source: The Motley Fool. Thursday, May 7, 2026 at 5 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Howard W. Robin Chief Research and...

Nektar Q1 2026 Earnings Transcript
TipRanks 6d
Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)

Reports Q1 revenue $10.86M, consensus $10.69M. “2026 is shaping up to be a defining year for Nektar (NKTR) and for our lead biologic candidate rezpegaldesleukin...

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.